BSX vs CI: Which Stock Is the Better Buy?
Boston Scientific Corporation and The Cigna Group side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BSX vs CI, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Boston Scientific Corporation (BSX) | The Cigna Group (CI) | |
|---|---|---|
| Market cap | $69.5B | $73.7B |
| Revenue (latest FY) | $20.07B | $274.90B |
| Net income (latest FY) | $2.90B | $5.96B |
| Revenue growth (5y CAGR) | 15.2% | 11.4% |
| Net margin | 14.4% | 2.2% |
| Return on equity | 12.0% | 14.3% |
| P/E ratio | 18.9 | 11.5 |
| Dividend yield | — | 2.2% |
| Profitable years (of last 10) | 9 | 10 |
| Positive free cash flow | Yes | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BSX vs CI breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BSX's full financials → Open CI's full financials →Frequently asked questions
Which is bigger, BSX or CI?
The Cigna Group is larger by market capitalization — $73.7B versus $69.5B.
Which grows faster, BSX or CI?
Over the last five fiscal years, Boston Scientific Corporation grew revenue faster — 15.2%/yr versus 11.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.